Key Drivers
- Strong Liquidity
- Persistent Losses
- Negative Cash Flow
AIAI Summary
AGIO is a catalyst-driven commercial and regulatory play, with its valuation hinging on the November 2026 sickle-cell PDUFA and subsequent mitapivat adoption; investors should prioritize evidence of launch-driven operating leverage, as approval failure or weak uptake would expose high cash burn and limited pipeline redundancy.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •Negative Cash Flow
AGIO has strong liquidity and minimal debt, but persistent losses, cash burn, declining book value, and a premium valuation make it a high-risk, future-outcome-dependent investment.
Price Behavior
Key Price Behavior Insights:
- •Range-bound trading
- •Support holding
- •Breakout needed
AGIO was mildly weak over the last month, holding $32.64–$33.00 support but lacking momentum unless it decisively clears $34.63.
Rebound to $34.63 failed to sustain
Sentiment & News
Key News Insights:
- •New institutional stake
- •198,685 shares
- •Q2 disclosure
BNY Mellon disclosed a new $7.37M stake in Agios Pharmaceuticals, signaling institutional interest in AGIO.
The sizable new position may support positive investor sentiment toward AGIO
Similar Companies in Healthcare
Other companies in the same sector with AI ratings